Asia
Aosaikang Pharmaceutical Gets Registration Certificate for Maribavir Tablets
Beijing Aosaikang Pharmaceutical (SHE:002755) received a drug registration certificate from China's National Medical Products Administration for Maribavir tablets, according to a Shenzhen bourse filing on Friday.The drug is used as a treatment for post-transplant refractory or resistant anti-cytomegalovirus of CMV infection or disease in pediatric patients.The pharmaceutical company's shares dipped 10% at the close.
SHE:002755
